|
US4732904A
(en)
*
|
1984-12-24 |
1988-03-22 |
Morgan Lee R |
Antiestrogenic hydrazones
|
|
US5075321A
(en)
*
|
1987-03-24 |
1991-12-24 |
University Of Pennsylvania |
Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
|
|
US5516790A
(en)
*
|
1989-01-23 |
1996-05-14 |
Texas A&M University System Technology Licensing Office |
Synthesis and application of alkyl-substituted dibenzofurans as antitumorigenic agents
|
|
DE4117512A1
(de)
*
|
1991-05-25 |
1992-11-26 |
Schering Ag |
2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
|
|
US5147880A
(en)
*
|
1991-07-22 |
1992-09-15 |
Eli Lilly And Company |
Benzo[a]fluorene compounds
|
|
US6515009B1
(en)
|
1991-09-27 |
2003-02-04 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US5811447A
(en)
|
1993-01-28 |
1998-09-22 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US5196435A
(en)
*
|
1991-11-21 |
1993-03-23 |
Eli Lilly And Company |
Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
|
|
TW366342B
(en)
*
|
1992-07-28 |
1999-08-11 |
Lilly Co Eli |
The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
|
|
USRE38968E1
(en)
*
|
1992-07-28 |
2006-02-07 |
Eli Lilly And Company |
Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
|
|
USRE39049E1
(en)
*
|
1992-07-28 |
2006-03-28 |
Eli Lilly And Company |
Methods for inhibiting bone loss
|
|
US6251920B1
(en)
|
1993-05-13 |
2001-06-26 |
Neorx Corporation |
Prevention and treatment of cardiovascular pathologies
|
|
US5770609A
(en)
*
|
1993-01-28 |
1998-06-23 |
Neorx Corporation |
Prevention and treatment of cardiovascular pathologies
|
|
US6395494B1
(en)
|
1993-05-13 |
2002-05-28 |
Neorx Corporation |
Method to determine TGF-β
|
|
TW383306B
(en)
*
|
1992-12-22 |
2000-03-01 |
Lilly Co Eli |
New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
|
|
US6491938B2
(en)
|
1993-05-13 |
2002-12-10 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US5595722A
(en)
*
|
1993-01-28 |
1997-01-21 |
Neorx Corporation |
Method for identifying an agent which increases TGF-beta levels
|
|
US5482949A
(en)
*
|
1993-03-19 |
1996-01-09 |
Eli Lilly And Company |
Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
|
|
US6197789B1
(en)
|
1995-06-07 |
2001-03-06 |
Neorx Corporation |
Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
|
|
ATE406909T1
(de)
*
|
1993-05-13 |
2008-09-15 |
Poniard Pharmaceuticals Inc |
Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
|
|
US5445941A
(en)
*
|
1993-06-21 |
1995-08-29 |
Eli Lilly And Company |
Method for screening anti-osteoporosis agents
|
|
ES2105525T3
(es)
*
|
1993-06-24 |
1997-10-16 |
Lilly Co Eli |
2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
|
|
TW303299B
(es)
*
|
1993-07-22 |
1997-04-21 |
Lilly Co Eli |
|
|
US6756388B1
(en)
*
|
1993-10-12 |
2004-06-29 |
Pfizer Inc. |
Benzothiophenes and related compounds as estrogen agonists
|
|
US5391557A
(en)
*
|
1993-10-15 |
1995-02-21 |
Eli Lilly And Company |
Methods for the treatment of peri-menopausal syndrome
|
|
US5461065A
(en)
*
|
1993-10-15 |
1995-10-24 |
Eli Lilly And Company |
Methods for inhibiting endometriosis
|
|
US5457116A
(en)
*
|
1993-10-15 |
1995-10-10 |
Eli Lilly And Company |
Methods of inhibiting uterine fibrosis
|
|
US5418252A
(en)
*
|
1993-10-15 |
1995-05-23 |
Eli Lilly And Company |
Method for inhibiting cartilage degradation
|
|
US5457113A
(en)
*
|
1993-10-15 |
1995-10-10 |
Eli Lilly And Company |
Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
|
|
US5482950A
(en)
*
|
1993-10-15 |
1996-01-09 |
Eli Lilly And Company |
Methods for lowering serum cholesterol
|
|
DE69430940T2
(de)
*
|
1993-10-15 |
2003-04-03 |
Eli Lilly And Co., Indianapolis |
Methode zur Behandlung von resistenten Neoplasmen
|
|
US5441964A
(en)
*
|
1993-10-15 |
1995-08-15 |
Eli Lilly And Company |
Methods for inhibiting bone loss using substituted benzothiophene
|
|
UA32427C2
(uk)
*
|
1993-10-15 |
2000-12-15 |
Елі Ліллі Енд Компані |
Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
|
|
US5480904A
(en)
*
|
1993-10-28 |
1996-01-02 |
Eli Lilly And Company |
Methods for inhibiting uterine fibrosis
|
|
US6489355B2
(en)
|
1993-12-01 |
2002-12-03 |
Eli Lilly And Company |
Methods of inhibiting the effects of amyloidogenic proteins
|
|
RU2135176C1
(ru)
*
|
1993-12-14 |
1999-08-27 |
Эли Лилли Энд Компани |
Водорастворенный комплекс включения соединений бензотиофена с водорастворимым циклодекстрином, способ его получения и фармацевтическая композиция
|
|
US6417198B1
(en)
|
1993-12-21 |
2002-07-09 |
Eli Lilly And Company |
Methods of inhibiting CNS problems in post-menopausal women
|
|
JPH09506898A
(ja)
*
|
1993-12-21 |
1997-07-08 |
イーライ・リリー・アンド・カンパニー |
非ペプチドタキキニン受容体アンタゴニスト
|
|
US5476862A
(en)
*
|
1993-12-21 |
1995-12-19 |
Eli Lilly And Company |
Methods of increasing thrombomodulin expression
|
|
US5447941A
(en)
*
|
1993-12-21 |
1995-09-05 |
Eli Lilly And Company |
Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
|
|
US5439931A
(en)
*
|
1993-12-21 |
1995-08-08 |
Eli Lilly And Company |
Method for increasing libido in post-menopausal women
|
|
US5552415A
(en)
*
|
1993-12-21 |
1996-09-03 |
Eli Lilly And Company |
Method of inhibiting Alzheimer's Disease
|
|
US5441966A
(en)
*
|
1993-12-21 |
1995-08-15 |
Eli Lilly And Company |
Methods of inhibiting Turner's syndrome
|
|
US5593987A
(en)
*
|
1993-12-21 |
1997-01-14 |
Eli Lilly And Company |
Methods of inhibiting breast disorders
|
|
US5439923A
(en)
*
|
1993-12-21 |
1995-08-08 |
Eli Lilly And Company |
Method of inhibiting seborrhea and acne
|
|
US5534526A
(en)
*
|
1993-12-21 |
1996-07-09 |
Eli Lilly And Company |
Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
|
|
US5451589A
(en)
*
|
1993-12-21 |
1995-09-19 |
Eli Lilly And Company |
Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism
|
|
US5441965A
(en)
*
|
1993-12-21 |
1995-08-15 |
Eli Lilly And Company |
Methods of inhibiting thrombin
|
|
US5462950A
(en)
*
|
1993-12-21 |
1995-10-31 |
Eli Lilly And Company |
Methods of treating menstrual symptoms and compositions therefore
|
|
HUT71466A
(en)
*
|
1993-12-21 |
1995-11-28 |
Lilly Co Eli |
Pharmaceutical compositions for inhibition of obsessive-compulsive and consumptive disorders containing 2-phenyl-3-aroyl-benzothiophene-derivatives and process for their preparation
|
|
US5672610A
(en)
*
|
1993-12-21 |
1997-09-30 |
Eli Lilly And Company |
Methods of increasing macrophage function
|
|
US5574047A
(en)
*
|
1993-12-21 |
1996-11-12 |
Eli Lilly And Company |
Methods of inhibiting imperfect tissue repair
|
|
US5446053A
(en)
*
|
1993-12-21 |
1995-08-29 |
Eli Lilly And Company |
Methods of inhibiting dysfunctional uterine bleeding
|
|
US5492927A
(en)
*
|
1993-12-21 |
1996-02-20 |
Eli Lilly And Company |
Non-peptide tachykinin receptor antagonists to treat allergy
|
|
CZ321394A3
(en)
*
|
1993-12-21 |
1995-08-16 |
Lilly Co Eli |
Pharmaceutical preparation for inhibiting woman hirsutism and alopecia
|
|
US5596004A
(en)
*
|
1993-12-21 |
1997-01-21 |
Eli Lilly And Company |
Methods of inhibiting male infertility
|
|
US5521198A
(en)
|
1993-12-21 |
1996-05-28 |
Eli Lilly And Company |
Methods of inhibiting autoimmune diseases
|
|
IL112034A
(en)
*
|
1993-12-21 |
1999-03-12 |
Lilly Co Eli |
Use of raloxifene and related compounds in the preparation of medicaments useful for the inhibition of ldl oxidation and atherosclerosis
|
|
US5462949A
(en)
*
|
1993-12-21 |
1995-10-31 |
Eli Lilly And Company |
Methods of inhibiting fertility in women
|
|
US5451590A
(en)
*
|
1993-12-21 |
1995-09-19 |
Eli Lilly & Co. |
Methods of inhibiting sexual precocity
|
|
US5461064A
(en)
*
|
1993-12-21 |
1995-10-24 |
Eli Lilly And Company |
Methods of inhibiting atrophy of the skin and vagina
|
|
US5708009A
(en)
*
|
1993-12-21 |
1998-01-13 |
Eli Lilly And Company |
Methods of inhibiting myeloperoxidase activity
|
|
US5578613A
(en)
*
|
1993-12-21 |
1996-11-26 |
Eli Lilly And Company |
Methods for inhibiting weight gain or inducing weight loss
|
|
US5389670A
(en)
*
|
1993-12-21 |
1995-02-14 |
Eli Lilly Company |
Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
|
|
US5591753A
(en)
*
|
1994-01-28 |
1997-01-07 |
Eli Lilly And Company |
Combination treatment for osteoporosis
|
|
US5478847A
(en)
*
|
1994-03-02 |
1995-12-26 |
Eli Lilly And Company |
Methods of use for inhibiting bone loss and lowering serum cholesterol
|
|
IL112746A
(en)
*
|
1994-03-02 |
1999-12-31 |
Lilly Co Eli |
Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
|
|
US5811120A
(en)
*
|
1994-03-02 |
1998-09-22 |
Eli Lilly And Company |
Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
|
|
US5972383A
(en)
*
|
1994-03-02 |
1999-10-26 |
Eli Lilly And Company |
Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
|
|
ATE214059T1
(de)
*
|
1994-04-11 |
2002-03-15 |
Chugai Pharmaceutical Co Ltd |
4,6-di-t-butyl-2,3-dihydrobenzothiophene, die ldl oxidation hemmen
|
|
US5604248A
(en)
*
|
1994-05-05 |
1997-02-18 |
Eli Lilly And Company |
Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
|
|
US5567820A
(en)
|
1994-05-20 |
1996-10-22 |
Eli Lilly And Company |
Glucopyranoside benzothiophenes
|
|
US5420349A
(en)
*
|
1994-06-10 |
1995-05-30 |
Eli Lilly And Company |
2-amino-3-aroyl-benzo[β]thiophenes and methods for preparing and using same to produce 6-hydroxy-2-(4-hydroxyphenyl)-3-]benzo[4-(2-aminoethoxy)-benzoyl[β]thiophenes
|
|
US5466810A
(en)
*
|
1994-06-10 |
1995-11-14 |
Eli Lilly And Company |
2-amino-3-aroyl-benzo[β]thiophenes and methods for preparing and using same to produce 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-aminoethoxy)-benzoyl]benzo[β]thiophenes
|
|
US5596106A
(en)
*
|
1994-07-15 |
1997-01-21 |
Eli Lilly And Company |
Cannabinoid receptor antagonists
|
|
TW398975B
(en)
|
1994-07-22 |
2000-07-21 |
Lilly Co Eli |
Pharmaceutical composition for inhibiting bone loss
|
|
US5523416A
(en)
*
|
1994-07-22 |
1996-06-04 |
Eli Lilly And Company |
Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes
|
|
US5496828A
(en)
|
1994-08-22 |
1996-03-05 |
Eli Lilly And Company |
Methods of inhibiting ulcerative mucositis
|
|
JPH10504824A
(ja)
*
|
1994-08-22 |
1998-05-12 |
イーライ・リリー・アンド・カンパニー |
子宮内膜癌を阻害する方法
|
|
US5434166A
(en)
*
|
1994-08-22 |
1995-07-18 |
Eli Lilly And Company |
Methods of inhibiting demyelinating and desmyelinating diseases
|
|
US5550123A
(en)
*
|
1994-08-22 |
1996-08-27 |
Eli Lilly And Company |
Methods for inhibiting bone prosthesis degeneration
|
|
US5550151A
(en)
*
|
1994-08-22 |
1996-08-27 |
Eli Lilly Company |
Methods of reducing scarring in wound healing
|
|
US5512296A
(en)
*
|
1994-08-22 |
1996-04-30 |
Eli Lilly And Company |
Methods for inhibiting neuronal damage
|
|
US5494920A
(en)
*
|
1994-08-22 |
1996-02-27 |
Eli Lilly And Company |
Methods of inhibiting viral replication
|
|
US5502074A
(en)
*
|
1994-08-22 |
1996-03-26 |
Eli Lilly And Company |
Benzothiophenes for bone healing and fracture repair
|
|
US5731436A
(en)
*
|
1994-08-31 |
1998-03-24 |
Eli Lilly And Company |
Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents
|
|
US5631369A
(en)
*
|
1994-08-31 |
1997-05-20 |
Eli Lilly And Company |
Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents
|
|
CO4410190A1
(es)
*
|
1994-09-19 |
1997-01-09 |
Lilly Co Eli |
3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
|
|
US5629425A
(en)
*
|
1994-09-19 |
1997-05-13 |
Eli Lilly And Company |
Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
|
|
US6703407B1
(en)
|
1994-09-20 |
2004-03-09 |
Eli Lilly And Company |
Benzofuran compounds, compositions, and methods
|
|
US7501441B1
(en)
|
1994-09-20 |
2009-03-10 |
Eli Lilly And Company |
Naphthyl compounds, intermediates, processes, compositions, and methods
|
|
US5492921A
(en)
*
|
1994-09-20 |
1996-02-20 |
Eli Lilly And Company |
Benzothiophene compounds, compositions, and methods for inhibiting aortal smooth muscle proliferation
|
|
US5554628A
(en)
*
|
1994-09-20 |
1996-09-10 |
Eli Lilly And Company |
Method for minimizing the uterothrophic effect of tamoxifen and tamoxifen analogs
|
|
US5658931A
(en)
*
|
1994-09-20 |
1997-08-19 |
Eli Lilly And Company |
Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds
|
|
US5843964A
(en)
*
|
1994-09-22 |
1998-12-01 |
Eli Lilly And Company |
Methods of inhibiting endometrial mitoses
|
|
IL115582A0
(en)
|
1994-10-14 |
1996-01-19 |
Lilly Co Eli |
Methods for treating resistant tumors
|
|
US5545641A
(en)
*
|
1994-10-20 |
1996-08-13 |
Eli Lilly And Company |
Methods of inhibiting physiological conditions associated with an excess of bradykinin
|
|
US6562862B1
(en)
*
|
1994-10-20 |
2003-05-13 |
Eli Lilly And Company |
Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
|
|
US5589482A
(en)
*
|
1994-12-14 |
1996-12-31 |
Pfizer Inc. |
Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
|
|
US5552412A
(en)
*
|
1995-01-09 |
1996-09-03 |
Pfizer Inc |
5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
|
|
US5494929A
(en)
*
|
1995-01-12 |
1996-02-27 |
Eli Lilly And Company |
Methods of inhibiting growth hormone effects
|
|
US5521214A
(en)
*
|
1995-01-25 |
1996-05-28 |
Eli Lilly And Company |
Methods of inhibiting environmental estrogens
|
|
US5512583A
(en)
*
|
1995-01-30 |
1996-04-30 |
Eli Lilly And Company |
Methods of decreasing serum calcium levels
|
|
CN1173819A
(zh)
*
|
1995-02-06 |
1998-02-18 |
伊莱利利公司 |
抑制il－6作用的方法
|
|
US5484808A
(en)
*
|
1995-02-09 |
1996-01-16 |
Eli Lilly And Company |
Methods of inhibiting cell-cell adhesion
|
|
US5821254A
(en)
*
|
1995-02-17 |
1998-10-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
|
|
US6479517B1
(en)
|
1995-02-28 |
2002-11-12 |
Eli Lilly And Company |
Phosphorous-containing benzothiophenes
|
|
US5856339A
(en)
*
|
1995-02-28 |
1999-01-05 |
Eli Lilly And Company |
Benzothiophene compounds, intermediates, compositions, and methods
|
|
EP0729956B1
(en)
*
|
1995-02-28 |
2001-10-31 |
Eli Lilly And Company |
Benzothiophene compounds, intermediates, compositions, and methods
|
|
US5856340A
(en)
|
1995-02-28 |
1999-01-05 |
Eli Lilly And Company |
Method of treating estrogen dependent cancers
|
|
US5998401A
(en)
|
1995-02-28 |
1999-12-07 |
Eli Lilly And Company |
Naphthyl compounds, intermediates, compositions, and methods
|
|
US5977093A
(en)
*
|
1995-02-28 |
1999-11-02 |
Eli Lilly And Company |
Benzothiophene compounds, intermediates, compositions, and methods
|
|
US5998441A
(en)
*
|
1995-02-28 |
1999-12-07 |
Eli Lilly And Company |
Benzothiophene compounds, intermediates, compositions, and methods
|
|
US5919800A
(en)
*
|
1995-02-28 |
1999-07-06 |
Eli Lilly And Company |
Benzothiophene compounds, intermediates, compositions, and methods
|
|
US5510357A
(en)
*
|
1995-02-28 |
1996-04-23 |
Eli Lilly And Company |
Benzothiophene compounds as anti-estrogenic agents
|
|
US6417199B1
(en)
|
1995-03-10 |
2002-07-09 |
Eli Lilly And Company |
3-benzyl-benzothiophenes
|
|
US6391892B1
(en)
|
1995-03-10 |
2002-05-21 |
Eli Lilly And Company |
Naphthyl pharmaceutical compounds
|
|
US6451817B1
(en)
|
1995-03-10 |
2002-09-17 |
Eli Lilly And Company |
Alpha-substituted-1-benzyl-napthyls
|
|
US6384053B1
(en)
|
1995-03-10 |
2002-05-07 |
Eli Lilly And Company |
α-substituted-1-benzyl-napthyls
|
|
US6395755B1
(en)
*
|
1995-03-10 |
2002-05-28 |
Eli Lilly And Company |
Benzothiophene pharmaceutical compounds
|
|
US5523309A
(en)
*
|
1995-03-10 |
1996-06-04 |
Eli Lilly And Company |
Benzofuran pharmaceutical compounds
|
|
US5622974A
(en)
*
|
1995-03-10 |
1997-04-22 |
Eli Lilly And Company |
α-substituted-3-benzyl-benzofurans
|
|
US6653328B1
(en)
|
1995-03-10 |
2003-11-25 |
Eli Lilly And Company |
3-benzyl-benzothiophenes
|
|
US5705507A
(en)
*
|
1995-03-10 |
1998-01-06 |
Eli Lilly And Company |
Aplha-substituted-3-benzyl-benzofurans
|
|
CA2214850A1
(en)
*
|
1995-03-13 |
1996-09-19 |
Eli Lilly And Company |
Novel benzothiophene compounds and methods
|
|
US5514704A
(en)
*
|
1995-03-13 |
1996-05-07 |
Eli Lilly And Company |
Benzothiophenes to inhibit leukotrienes
|
|
US5532382A
(en)
*
|
1995-03-13 |
1996-07-02 |
Eli Lilly And Company |
Benzothiophenes substituted at the 3-carbonyl
|
|
US5514703A
(en)
*
|
1995-03-13 |
1996-05-07 |
Eli Lilly And Company |
Benzothiophene compounds useful for inhibiting lipoxygenase
|
|
US20040167080A1
(en)
*
|
1995-03-15 |
2004-08-26 |
Dodge Jeffrey A. |
Glucopyranoside benzothiophenes
|
|
US5614639A
(en)
*
|
1995-03-31 |
1997-03-25 |
Eli Lilly And Company |
Process for preparing 2-substituted benzo[b]thiophene compounds and intermediates thereof
|
|
US5563054A
(en)
*
|
1995-03-31 |
1996-10-08 |
Eli Lilly And Company |
Process for preparation of benzo[B]thiophene glucuronides
|
|
US6608090B1
(en)
|
1995-04-21 |
2003-08-19 |
Eli Lilly And Company |
Benzothiophenes with novel basic side chains
|
|
EP0738725A3
(en)
*
|
1995-04-21 |
1997-03-05 |
Lilly Co Eli |
Benzothiophenes with basic side chains
|
|
US5622975A
(en)
*
|
1995-06-01 |
1997-04-22 |
Eli Lilly And Company |
Methods for inhibiting vascular smooth muscle cell migration
|
|
US5599822A
(en)
*
|
1995-06-06 |
1997-02-04 |
Eli Lilly And Company |
Methods for minimizing bone loss
|
|
US5843974A
(en)
*
|
1995-06-06 |
1998-12-01 |
Eli Lilly And Company |
Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
|
|
US5567828A
(en)
*
|
1995-06-07 |
1996-10-22 |
Eli Lilly And Company |
Compounds and compositions with nitrogen-containing non-basic side
|
|
US5532254A
(en)
*
|
1995-06-07 |
1996-07-02 |
Eli Lilly And Company |
Modulation of calcium channels using benzothiophenes
|
|
US5840747A
(en)
*
|
1995-06-07 |
1998-11-24 |
Eli Lilly And Company |
Calcium channel antagonists
|
|
US6545027B1
(en)
|
1995-06-07 |
2003-04-08 |
Eli Lilly And Company |
Methods of modulating NF-kB transcription factor
|
|
DE69622472T2
(de)
*
|
1995-06-07 |
2003-02-06 |
Eli Lilly And Co., Indianapolis |
Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor
|
|
US6444688B1
(en)
|
1995-06-07 |
2002-09-03 |
Eli Lilly And Company |
Compounds and compositions with nitrogen-containing non-basic side chains
|
|
DE69611452T2
(de)
|
1995-06-26 |
2001-06-13 |
Eli Lilly And Co., Indianapolis |
Benzothiophenderivate
|
|
US5811421A
(en)
*
|
1995-07-31 |
1998-09-22 |
Eli Lilly And Company |
Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods
|
|
US5728724A
(en)
*
|
1995-08-17 |
1998-03-17 |
Eli Lilly And Company |
Benzothiophene compounds
|
|
US5726186A
(en)
*
|
1995-09-08 |
1998-03-10 |
Eli Lilly And Company |
Pentacyclic compounds, intermediates, processes, compositions, and methods
|
|
US5731328A
(en)
*
|
1995-10-10 |
1998-03-24 |
Eli Lilly And Company |
Methods of inhibiting plasminogen activator inhibitor 1
|
|
US5726168A
(en)
*
|
1995-10-12 |
1998-03-10 |
Eli Lilly And Company |
Lipophilic benzothiophenes
|
|
US5670523A
(en)
*
|
1996-01-29 |
1997-09-23 |
Eli Lilly And Company |
Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
|
|
US6113876A
(en)
*
|
1996-01-29 |
2000-09-05 |
Eli Lilly And Company |
Methods of increasing sphincter competence
|
|
US6432982B1
(en)
*
|
1996-02-21 |
2002-08-13 |
Eli Lilly And Company |
Benzothiophenes, and formulations and methods using same
|
|
US5731342A
(en)
*
|
1996-02-22 |
1998-03-24 |
Eli Lilly And Company |
Benzothiophenes, formulations containing same, and methods
|
|
TW442286B
(en)
*
|
1996-02-28 |
2001-06-23 |
Pfizer |
New therapeutic uses of estrogen agonists
|
|
HN1996000101A
(es)
|
1996-02-28 |
1997-06-26 |
Inc Pfizer |
Terapia combinada para la osteoporosis
|
|
IL120266A
(en)
|
1996-02-28 |
2005-05-17 |
Pfizer |
Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
|
|
US5688796A
(en)
*
|
1996-03-12 |
1997-11-18 |
Eli Lilly And Company |
Heterocyclic substituted benzothiophenes, compositions, and methods
|
|
EP0888331A4
(en)
*
|
1996-03-19 |
2001-05-23 |
Lilly Co Eli |
SYNTHESIS OF 3- [4- (2-AMINOETHOXY) BENZOYL] -2-ARYL-6-HYDROXY-BENZO [b] THIOPHENES
|
|
US6458811B1
(en)
*
|
1996-03-26 |
2002-10-01 |
Eli Lilly And Company |
Benzothiophenes formulations containing same and methods
|
|
JP2000507268A
(ja)
*
|
1996-03-26 |
2000-06-13 |
イーライ・リリー・アンド・カンパニー |
ベンゾチオフェン類、それを含む製剤、および方法
|
|
US5811437A
(en)
*
|
1996-05-21 |
1998-09-22 |
Eli Lilly And Company |
Methods of increasing nitric oxide synthesis
|
|
US5747509A
(en)
*
|
1996-06-03 |
1998-05-05 |
Schering Aktiengesellschaft |
Method for lowering plasma levels of lipoprotein(a)
|
|
US6110942A
(en)
*
|
1996-06-17 |
2000-08-29 |
Eli Lilly And Company |
Method for minimizing the uterotrophic effect of droloxifene
|
|
US6350884B1
(en)
|
1996-06-25 |
2002-02-26 |
Eli Lilly And Company |
Acrylic and propionic acid compounds, intermediates, processes, compositions, and method
|
|
CA2206752A1
(en)
*
|
1996-07-02 |
1998-01-02 |
George Joseph Cullinan |
Benzothiophene compounds, intermediates, processes, and methods of use
|
|
CA2207141A1
(en)
*
|
1996-07-15 |
1998-01-15 |
David Thompson Berg |
Benzothiophene compounds, and uses and formulations thereof
|
|
US5980938A
(en)
*
|
1996-07-15 |
1999-11-09 |
Eli Lilly And Company |
Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
|
|
US5672609A
(en)
*
|
1996-07-18 |
1997-09-30 |
Eli Lilly And Company |
Pyridine compounds, intermediates compositions and methods of use
|
|
US5792798A
(en)
*
|
1996-07-29 |
1998-08-11 |
Eli Lilly And Company |
Method for inhibiting plasminogen activator inhibitor 1
|
|
US6713494B1
(en)
|
1996-08-28 |
2004-03-30 |
Eli Lilly And Company |
Amorphous benzothiophenes, methods of preparation and methods of use
|
|
ID19392A
(id)
*
|
1996-08-29 |
1998-07-09 |
Lilly Co Eli |
Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
|
|
CA2214070C
(en)
*
|
1996-08-29 |
2006-03-14 |
Eli Lilly And Company |
Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
|
|
US6599920B2
(en)
|
1996-08-29 |
2003-07-29 |
Eli Lilly And Company |
Naphthalene compounds, intermediates, formulations, and methods
|
|
CA2213810C
(en)
*
|
1996-08-29 |
2006-06-06 |
Lewis Dale Pennington |
Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods
|
|
CA2214072C
(en)
*
|
1996-08-29 |
2006-11-14 |
Eli Lilly And Company |
Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
|
|
CA2214919A1
(en)
*
|
1996-09-24 |
1998-03-24 |
Kenneth Lee Hauser |
Benzothiophene compounds, intermediates, processes, compositions, and methods
|
|
PE2699A1
(es)
*
|
1996-09-25 |
1999-02-04 |
Lilly Co Eli |
Procedimiento para la sintesis de benzotiofenos
|
|
CA2215856A1
(en)
*
|
1996-09-26 |
1998-03-26 |
Eli Lilly And Company |
Dihydrobenzofluorene compounds, intermediates, compositions, and methods
|
|
CA2214929A1
(en)
*
|
1996-09-26 |
1998-03-26 |
Charles Willis Lugar, Iii |
Naphthofluorene compounds, intermediates, compositions and methods
|
|
CA2214935A1
(en)
*
|
1996-09-26 |
1998-03-26 |
Henry Uhlman Bryant |
Benzofluorene compounds, intermediates, compositions, and methods
|
|
CA2214196A1
(en)
*
|
1996-09-26 |
1998-03-26 |
Eli Lilly And Company |
Benzo[b]indeno[2,1-d]thiophene compounds, intermediates, processes, compositions and methods
|
|
CA2214931A1
(en)
*
|
1996-09-26 |
1998-03-26 |
Henry Uhlman Bryant |
Tetrahydrobenzo-a-fluorene compounds and method of use
|
|
CA2214922A1
(en)
*
|
1996-09-27 |
1998-03-27 |
Eli Lilly And Company |
Benzothiophene compounds, compositions, and methods
|
|
US5948796A
(en)
*
|
1996-10-10 |
1999-09-07 |
Eli Lilly And Company |
Benzo B!thiophene compounds, intermediates, formulations, and methods
|
|
US5958969A
(en)
*
|
1996-10-10 |
1999-09-28 |
Eli Lilly And Company |
Benzo b!thiophene compounds, intermediates, formulations, and methods
|
|
US5916916A
(en)
*
|
1996-10-10 |
1999-06-29 |
Eli Lilly And Company |
1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
|
|
CA2216592C
(en)
*
|
1996-10-24 |
2006-07-18 |
Brian Stephen Muehl |
Benzothiophene compounds, intermediates, compositions, and methods
|
|
CA2215647A1
(en)
*
|
1996-10-24 |
1998-04-24 |
Eli Lilly And Company |
Naphthyl compounds, compositions, and methods
|
|
CA2214872C
(en)
*
|
1996-10-24 |
2002-01-22 |
Eli Lilly And Company |
Benzothiophene compounds, compositions and methods
|
|
US5773432A
(en)
*
|
1996-10-30 |
1998-06-30 |
Schering Aktiengesellschaft |
Method for lowering plasma levels of lipoprotein(a)
|
|
ZA979720B
(en)
|
1996-10-30 |
1999-04-29 |
Lilly Co Eli |
Prophylaxis of breast cancer
|
|
YU42397A
(sh)
*
|
1996-10-30 |
2000-10-30 |
Eli Lilly And Company |
Korišćenje raloksifena za pripremu leka
|
|
KR100522646B1
(ko)
*
|
1996-10-30 |
2005-12-21 |
일라이 릴리 앤드 캄파니 |
유방암의예방방법
|
|
GB9624800D0
(en)
*
|
1996-11-29 |
1997-01-15 |
Lilly Co Eli |
Methods of preventing breast cancer
|
|
ZA9710262B
(en)
*
|
1996-11-19 |
1999-05-13 |
Lilly Co Eli |
Process for the synthesis of benzothiophenes
|
|
ZA982877B
(en)
*
|
1997-04-09 |
1999-10-04 |
Lilly Co Eli |
Treatment of central nervous system disorders with selective estrogen receptor modulators.
|
|
US6117911A
(en)
*
|
1997-04-11 |
2000-09-12 |
Neorx Corporation |
Compounds and therapies for the prevention of vascular and non-vascular pathologies
|
|
US6025373A
(en)
*
|
1997-04-22 |
2000-02-15 |
Eli Lilly And Company |
Methods for reducing fibrinogen
|
|
AU7467398A
(en)
*
|
1997-04-25 |
1998-11-24 |
Eli Lilly And Company |
Indene compounds having activity as serms
|
|
CN1252717A
(zh)
*
|
1997-04-30 |
2000-05-10 |
伊莱利利公司 |
制备苯并[b]噻吩的中间体和方法
|
|
AU7274198A
(en)
*
|
1997-04-30 |
1998-11-24 |
Eli Lilly And Company |
Antithrombotic agents
|
|
CA2231013A1
(en)
*
|
1997-04-30 |
1998-10-30 |
Eli Lilly And Company |
Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals
|
|
AU7274098A
(en)
|
1997-04-30 |
1998-11-24 |
Eli Lilly And Company |
Antithrombotic agents
|
|
WO1998048792A1
(en)
*
|
1997-04-30 |
1998-11-05 |
Eli Lilly And Company |
A REGIOSELECTIVE ALKYLATION PROCESS FOR PREPARING SUBSTITUTED BENZO[b]THIOPHENES
|
|
BR9809439A
(pt)
*
|
1997-04-30 |
2000-06-13 |
Lilly Co Eli |
Processos para preparação de benzotiofenos
|
|
JP2001523253A
(ja)
*
|
1997-04-30 |
2001-11-20 |
イーライ・リリー・アンド・カンパニー |
ベンゾ［ｂ］チオフェン類の製造のための中間体および方法
|
|
JP2002501503A
(ja)
|
1997-04-30 |
2002-01-15 |
イーライ・リリー・アンド・カンパニー |
抗血栓症剤
|
|
CA2288144A1
(en)
|
1997-04-30 |
1998-11-05 |
Eli Lilly And Company |
Antithrombotic agents
|
|
CA2236254A1
(en)
*
|
1997-04-30 |
1998-10-30 |
David Warren Hoard |
Process for preparing benzo¬b|thiophenes
|
|
US5760030A
(en)
*
|
1997-06-30 |
1998-06-02 |
Eli Lilly And Company |
Benzothiophene compounds and methods of use
|
|
CA2298651A1
(en)
|
1997-08-07 |
1999-02-18 |
Jeffrey Alan Dodge |
1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity
|
|
US5908859A
(en)
*
|
1997-08-11 |
1999-06-01 |
Eli Lilly And Company |
Benzothiophenes for inhibiting hyperlipidemia
|
|
US6090843A
(en)
*
|
1997-08-11 |
2000-07-18 |
Eli Lilly And Company |
Benzothiophenes compounds which have useful pharmaceutical activity
|
|
US6008232A
(en)
*
|
1997-08-20 |
1999-12-28 |
Eli Lilly And Company |
Methods for preventing headaches
|
|
US6103740A
(en)
*
|
1997-08-21 |
2000-08-15 |
Eli Lilly And Company |
Methods for lowering platelet counts
|
|
US6017914A
(en)
*
|
1997-09-03 |
2000-01-25 |
Eli Lilly And Company |
Benzo[b]thiophene compounds, intermediates, formulations, and methods
|
|
US5929090A
(en)
*
|
1997-09-12 |
1999-07-27 |
Eli Lilly And Company |
2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
|
|
US5834488A
(en)
*
|
1997-09-19 |
1998-11-10 |
Eli Lilly And Company |
Dihydrobenzo B! indeno 2, 1-D! thiophene compounds, intermediates, processes, compositions and methods
|
|
US5990129A
(en)
*
|
1997-09-23 |
1999-11-23 |
Eli Lilly And Company |
Methods for regulating trkA expression
|
|
AU9399898A
(en)
|
1997-10-03 |
1999-04-27 |
Eli Lilly And Company |
Benzothiophenes
|
|
US6096781A
(en)
|
1997-11-14 |
2000-08-01 |
Eli Lilly And Company |
2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
|
|
ID24978A
(id)
*
|
1997-11-14 |
2000-08-31 |
Lilly Co Eli |
2-ARYL-3-AROYLBENZO (b) THIOPHENES BERGUNA UNTUK PENGOBATAN SINDROM DEPRIVASI ESTROGEN
|
|
WO1999051096A1
(en)
*
|
1998-04-08 |
1999-10-14 |
Eli Lilly And Company |
Pulmonary and nasal delivery of raloxifene
|
|
FR2777784B1
(fr)
*
|
1998-04-27 |
2004-03-19 |
Arepa |
Composition pharmaceutique a base d'estrogene et de progesterone
|
|
US6284756B1
(en)
|
1998-04-30 |
2001-09-04 |
Eli Lilly And Company |
Antithrombotic agents
|
|
US20040176470A1
(en)
*
|
1998-05-07 |
2004-09-09 |
Steiner Mitchell S. |
Method for treatment and chemoprevention of prostate cancer
|
|
US20040092602A1
(en)
*
|
1998-05-07 |
2004-05-13 |
Steiner Mitchell S. |
Method for treatment and chemoprevention of prostate cancer
|
|
US20030130316A1
(en)
*
|
2000-03-20 |
2003-07-10 |
Steiner Mitchell S. |
Method for chemoprevention of prostate cancer
|
|
US6413533B1
(en)
*
|
1998-05-07 |
2002-07-02 |
The University Of Tennessee Research Corporation |
Method for chemoprevention of prostate cancer
|
|
US6465445B1
(en)
*
|
1998-06-11 |
2002-10-15 |
Endorecherche, Inc. |
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
|
|
US6353003B1
(en)
|
1998-06-17 |
2002-03-05 |
Eli Lilly And Company |
Method for reducing levels of homocysteine and C-reactive protein
|
|
US6060488A
(en)
*
|
1998-09-22 |
2000-05-09 |
Eli Lilly And Company |
Benzothiophenes for treating estrogen deficiency
|
|
US6258826B1
(en)
|
1998-10-13 |
2001-07-10 |
Eli Lilly And Company |
Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
|
|
ES2189355T3
(es)
*
|
1998-10-28 |
2003-07-01 |
Lilly Co Eli |
Compuestos de benzotiofeno como agentes antitromboticos e intermedios.
|
|
US6410565B1
(en)
|
1999-02-03 |
2002-06-25 |
Eli Lilly And Company |
α1-adrenergic receptor antagonists
|
|
US6300367B1
(en)
|
1999-04-20 |
2001-10-09 |
Protein Technologies International, Inc. |
Composition for and method of preventing or treating breast cancer
|
|
HUP0200871A3
(en)
|
1999-05-04 |
2004-04-28 |
Strakan Int Ltd |
Androgen glycosides and androgenic activity thereof
|
|
US6380166B1
(en)
|
1999-09-13 |
2002-04-30 |
American Home Products Corporation |
Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
|
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
|
EP1113007A1
(en)
|
1999-12-24 |
2001-07-04 |
Pfizer Inc. |
Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
|
|
US20020013327A1
(en)
*
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
ES2518926T3
(es)
|
2000-06-02 |
2014-11-05 |
Board Of Regents, The University Of Texas System |
Conjugados de etilendicisteína y un análogo de glucosa
|
|
AR029538A1
(es)
*
|
2000-07-06 |
2003-07-02 |
Wyeth Corp |
Composiciones farmaceuticas de agentes estrogenicos
|
|
AU2002230409A1
(en)
*
|
2000-11-27 |
2002-06-03 |
Eli Lilly And Company |
Process for preparing 3-aryl-benzo(b)thiophenes
|
|
AU2002228593A8
(en)
*
|
2000-11-27 |
2008-06-12 |
Lilly Co Eli |
Process for preparing alpha-(3-arylthio)-acetophenones
|
|
AU2002235348A1
(en)
*
|
2001-01-17 |
2002-07-30 |
Praecis Pharmaceuticals Inc. |
Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
|
|
AU781168B2
(en)
|
2001-01-26 |
2005-05-12 |
Pfizer Products Inc. |
Method of treating certain cancers using an estrogen agonist/antagonist
|
|
CA2444383A1
(en)
*
|
2001-04-26 |
2002-11-07 |
Board Of Regents, The University Of Texas System |
Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
|
|
US6613083B2
(en)
|
2001-05-02 |
2003-09-02 |
Eckhard Alt |
Stent device and method
|
|
US7425565B2
(en)
*
|
2002-05-09 |
2008-09-16 |
Cedars-Sinai Medical Center |
Use of benzothiopenes to treat and prevent prostate cancer
|
|
EP1401446B1
(en)
*
|
2001-05-22 |
2005-02-09 |
Eli Lilly And Company |
Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
|
|
WO2002094788A1
(en)
*
|
2001-05-22 |
2002-11-28 |
Eli Lilly And Company |
2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
|
|
US20030216358A1
(en)
*
|
2001-07-05 |
2003-11-20 |
Muchmore Douglas Boyer |
Method for enhancing bone mineral density gain
|
|
US20040044224A1
(en)
*
|
2001-08-21 |
2004-03-04 |
Conrad Preston Charles |
Process for preparing 2-phenyl-3-aminobenzothiophenes
|
|
EP1312363A1
(en)
*
|
2001-09-28 |
2003-05-21 |
Pfizer Products Inc. |
Methods of treatment and kits comprising a growth hormone secretagogue
|
|
WO2003039466A2
(en)
*
|
2001-11-06 |
2003-05-15 |
Applied Research Systems Ars Holding N.V. |
Method of treating estrogen responsive breast cancer
|
|
US20080249183A1
(en)
*
|
2001-11-29 |
2008-10-09 |
Steiner Mitchell S |
Treatment of androgen-deprivation induced osteoporosis
|
|
US7261875B2
(en)
*
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
|
AU2003217676B2
(en)
|
2002-02-22 |
2009-06-11 |
Takeda Pharmaceutical Company Limited |
Active agent delivery systems and methods for protecting and administering active agents
|
|
US7342884B2
(en)
*
|
2002-03-13 |
2008-03-11 |
Harmonic, Inc. |
Method and apparatus for one directional communications in bidirectional communications channel
|
|
MXPA05000898A
(es)
*
|
2002-07-22 |
2005-05-16 |
Lilly Co Eli |
Moduladores de receptor de estrogeno selectivos que contiene, un grupo fenilsulfonilo.
|
|
US6933292B2
(en)
*
|
2002-07-30 |
2005-08-23 |
Children's Medical Center Corporation |
Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
|
|
AU2003266940B2
(en)
*
|
2002-09-30 |
2007-02-08 |
A/S Gea Farmaceutisk Fabrik |
Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
|
|
US20040138180A1
(en)
*
|
2002-10-03 |
2004-07-15 |
Barr Laboratories, Inc. |
Bisphosphonate composition and process for the preparation thereof
|
|
WO2004044227A2
(en)
*
|
2002-11-07 |
2004-05-27 |
Board Of Regents, The University Of Texas System |
Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging
|
|
AU2003292625B2
(en)
*
|
2002-12-26 |
2008-07-24 |
Eisai R & D Management Co., Ltd. |
Selective estrogen receptor modulators
|
|
TWI299664B
(en)
*
|
2003-01-06 |
2008-08-11 |
Osi Pharm Inc |
(2-carboxamido)(3-amino)thiophene compounds
|
|
US7332525B2
(en)
*
|
2003-01-17 |
2008-02-19 |
Castle Erik P |
Method of treatment of prostate cancer and composition for treatment thereof
|
|
US7279600B2
(en)
*
|
2003-05-02 |
2007-10-09 |
Wyeth |
Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents
|
|
JP2007503466A
(ja)
*
|
2003-05-16 |
2007-02-22 |
ワイス |
アリール−カルボアルデヒドオキシム誘導体およびエストロゲン様物質としてのその使用
|
|
CN1548434B
(zh)
*
|
2003-05-16 |
2010-07-28 |
中国科学院上海药物研究所 |
一类苯并噻吩类化合物、及制备和它的医药用途
|
|
CL2004000985A1
(es)
*
|
2003-05-16 |
2005-01-14 |
Wyeth Corp |
Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
|
|
US20060106010A1
(en)
*
|
2003-05-27 |
2006-05-18 |
Black Larry J |
Methods for inhibiting bone loss
|
|
US20040248989A1
(en)
|
2003-06-05 |
2004-12-09 |
Risto Santti |
Method for the treatment or prevention of lower urinary tract symptoms
|
|
ITMI20031333A1
(it)
*
|
2003-06-30 |
2005-01-01 |
Erregierre Spa |
Processo di preparazione di raloxifene cloridrato.
|
|
US7250440B2
(en)
*
|
2003-08-12 |
2007-07-31 |
Wyeth |
(Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents
|
|
CA2539361A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Pfizer Products Inc. |
Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
|
|
DE10349249A1
(de)
*
|
2003-10-20 |
2005-05-12 |
Basf Ag |
Verfahren zur Herstellung von alpha-(3-Arylthio)-acetophenonen
|
|
BRPI0416639A
(pt)
|
2003-11-19 |
2007-01-16 |
Metabasis Therapeutics Inc |
tiromiméticos contendo fósforo
|
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
|
MXPA06006810A
(es)
*
|
2003-12-17 |
2006-08-23 |
Pfizer Prod Inc |
Tratamiento de afecciones que se presentan con un nivel bajo de masa osea por terapia de combinacion continua con agonistas selectivos del receptor de prostaglandina ep4 y un estrogeno.
|
|
US7012153B2
(en)
|
2003-12-22 |
2006-03-14 |
Eli Lilly And Company |
Process for preparing benzoic acids
|
|
US20050137264A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Patel Ashish A. |
Modafinil compositions
|
|
US7157492B2
(en)
|
2004-02-26 |
2007-01-02 |
Wyeth |
Dibenzo chromene derivatives and their use as ERβ selective ligands
|
|
EP3006039B1
(en)
|
2004-03-02 |
2021-01-06 |
Acceleron Pharma Inc. |
Alk7 polypeptides for use in promoting fat loss
|
|
US20050203086A1
(en)
*
|
2004-03-04 |
2005-09-15 |
Pfizer Inc. |
Methods of treatment using an EP2 selective receptor agonist
|
|
MXPA06011685A
(es)
*
|
2004-04-08 |
2006-12-14 |
Wyeth Corp |
Formulaciones de dispersiones solidas de acetato de bazedoxifeno.
|
|
CN1946689A
(zh)
*
|
2004-04-08 |
2007-04-11 |
惠氏公司 |
作为选择性雌激素受体调节剂的巴西多昔芬抗坏血酸盐
|
|
CN1993343A
(zh)
*
|
2004-07-01 |
2007-07-04 |
惠氏公司 |
作为雌激素配体的四环化合物
|
|
EP1781628A2
(en)
*
|
2004-08-26 |
2007-05-09 |
Wyeth a Corporation of the State of Delaware |
Prodrug substituted benzoxazoles as estrogenic agents
|
|
US20060293294A1
(en)
*
|
2004-09-03 |
2006-12-28 |
Hormos Medical Corporation |
Method for treatment or prevention of androgen deficiency
|
|
AU2005282554A1
(en)
*
|
2004-09-07 |
2006-03-16 |
Wyeth |
6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents
|
|
US20060068010A1
(en)
*
|
2004-09-30 |
2006-03-30 |
Stephen Turner |
Method for improving the bioavailability of orally delivered therapeutics
|
|
AU2005308575A1
(en)
*
|
2004-11-23 |
2006-06-01 |
Warner-Lambert Company Llc |
7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
|
|
UA89513C2
(uk)
*
|
2004-12-03 |
2010-02-10 |
Элан Фарма Интернешнл Лтд. |
Стабільна композиція з наночастинок ралоксифену гідрохлориду
|
|
ES2552338T3
(es)
|
2005-01-21 |
2015-11-27 |
Astex Therapeutics Limited |
Compuestos farmacéuticos
|
|
US20060270641A1
(en)
*
|
2005-05-31 |
2006-11-30 |
Steiner Mitchell S |
Method for chemoprevention of prostate cancer
|
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
|
BRPI0711525A2
(pt)
|
2006-06-02 |
2011-11-01 |
Pear Tree Women S Health Care |
composição farmacêutica e método para tratar sintomas de vaginite atrófica
|
|
EP2054042B8
(en)
|
2006-06-30 |
2020-06-10 |
iCeutica Pty Ltd |
Methods for the preparation of biologically active compounds in nanoparticulate form
|
|
US10925977B2
(en)
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
|
JP5528807B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
WO2008047105A1
(en)
*
|
2006-10-17 |
2008-04-24 |
Cipla Limited |
Crystalline form of benzothiophene compound and process for preparation thereof
|
|
ATE547394T1
(de)
|
2006-12-01 |
2012-03-15 |
Bristol Myers Squibb Co |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
|
|
WO2009008000A2
(en)
*
|
2007-04-12 |
2009-01-15 |
Sun Pharmaceutical Industries Ltd. |
A process for the preparation of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidino ethoxy) benzoyl]benzo[b]thiophene
|
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
|
AR068332A1
(es)
|
2007-08-03 |
2009-11-11 |
Summit Corp Plc |
Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne
|
|
US20090069381A1
(en)
*
|
2007-09-12 |
2009-03-12 |
Protia, Llc |
Deuterium-enriched raloxifene
|
|
JP5558358B2
(ja)
|
2007-10-16 |
2014-07-23 |
レプロス セラピューティクス インコーポレイティド |
メタボリック症候群用のｔｒａｎｓ−クロミフェン
|
|
CL2008003799A1
(es)
*
|
2007-12-21 |
2009-12-18 |
Synthon Bv |
Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
|
|
WO2009146097A1
(en)
*
|
2008-04-02 |
2009-12-03 |
Dr. Reddy's Laboratories Ltd. |
Raloxifene pharmaceutical formulations
|
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
US8551973B2
(en)
*
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
|
EP2671888A1
(en)
|
2008-12-23 |
2013-12-11 |
Gilead Pharmasset LLC |
3',5'-cyclic nucleoside phosphate analogues
|
|
AR074897A1
(es)
|
2008-12-23 |
2011-02-23 |
Pharmasset Inc |
Fosforamidatos de nucleosidos
|
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
|
UA106231C2
(uk)
|
2009-04-24 |
2014-08-11 |
Айсьютика Пти Лтд |
Разова доза фармацевтичної композиції індометацину (варіанти)
|
|
ES2437916T3
(es)
|
2009-07-02 |
2014-01-15 |
Synthon B.V. |
Composición de raloxifeno
|
|
WO2011123645A2
(en)
|
2010-03-31 |
2011-10-06 |
Pharmasset, Inc. |
Nucleoside phosphoramidates
|
|
US8501690B2
(en)
|
2010-04-30 |
2013-08-06 |
John G. Stark |
Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
|
|
CA2857061A1
(en)
|
2011-12-16 |
2013-06-20 |
Olema Pharmaceuticals, Inc. |
Novel benzopyran compounds, compositions and uses thereof
|
|
US20140378422A1
(en)
|
2012-01-31 |
2014-12-25 |
Novartis Ag |
Combination of a RTK inhibitor with an anti-estrogen and use thereof for the treatment of cancer
|
|
EP3300725A3
(en)
|
2012-02-14 |
2018-05-16 |
Repros Therapeutics Inc. |
Selective estrogen receptor modulators with short half-lives and uses thereof
|
|
HK1204979A1
(en)
|
2012-02-29 |
2015-12-11 |
Repros Therapeutics Inc. |
Combination therapy for treating androgen deficiency
|
|
PE20151428A1
(es)
|
2013-02-19 |
2015-09-24 |
Novartis Ag |
Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrogeno
|
|
WO2014203132A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Substituted benzopyran compounds, compositions and uses thereof
|
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
|
US9421264B2
(en)
|
2014-03-28 |
2016-08-23 |
Duke University |
Method of treating cancer using selective estrogen receptor modulators
|
|
PL3122426T3
(pl)
|
2014-03-28 |
2023-05-15 |
Duke University |
Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego
|
|
US9526734B2
(en)
|
2014-06-09 |
2016-12-27 |
Iceutica Pty Ltd. |
Formulation of meloxicam
|
|
HK1244673A1
(zh)
|
2015-01-28 |
2018-08-17 |
韩美药品株式会社 |
包括雷洛昔芬以及维生素d或其衍生物的复合胶囊
|
|
CN108366996B
(zh)
|
2015-10-01 |
2021-04-09 |
奥列马制药公司 |
四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物
|
|
JP7048505B2
(ja)
|
2015-11-10 |
2022-04-05 |
パラクリン セラピューティクス エービー |
Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置
|
|
US10118910B2
(en)
|
2015-12-09 |
2018-11-06 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective estrogen receptor downregulators
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
EP4483875A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
WO2017197051A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Amine-linked c3-glutarimide degronimers for target protein degradation
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
EP3858835A1
(en)
|
2016-07-01 |
2021-08-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based antiproliferative agents
|
|
WO2018081168A2
(en)
|
2016-10-24 |
2018-05-03 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective mixed estrogen receptor downregulators
|
|
TWI619697B
(zh)
|
2016-12-01 |
2018-04-01 |
國立中山大學 |
亞碸化合物及其用於製造苯並噻吩衍生物之方法
|
|
JP7229162B2
(ja)
|
2017-01-06 |
2023-02-27 |
ジー１ セラピューティクス， インコーポレイテッド |
癌の治療に対する併用療法
|
|
KR20190117582A
(ko)
|
2017-02-10 |
2019-10-16 |
쥐원 쎄라퓨틱스, 인크. |
벤조티오펜 에스트로겐 수용체 조정제
|
|
AU2018291026B2
(en)
|
2017-06-29 |
2022-09-01 |
G1 Therapeutics, Inc. |
Morphic forms of GIT38 and methods of manufacture thereof
|
|
CN111801098A
(zh)
|
2018-02-21 |
2020-10-20 |
人工智能治疗公司 |
使用阿匹莫德和谷氨酸能剂的组合疗法
|
|
CN113453679B
(zh)
|
2018-12-20 |
2025-07-08 |
C4医药公司 |
靶向蛋白降解
|
|
MX2022007659A
(es)
|
2019-12-20 |
2022-07-19 |
C4 Therapeutics Inc |
Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr).
|
|
EP4114392A4
(en)
|
2020-03-05 |
2024-04-10 |
C4 Therapeutics, Inc. |
Compounds for targeted degradation of brd9
|
|
EP4192458A4
(en)
|
2020-08-05 |
2024-09-04 |
C4 Therapeutics, Inc. |
COMPOUNDS FOR TARGETED DEGRADATION OF RET
|
|
WO2024030968A1
(en)
|
2022-08-03 |
2024-02-08 |
Brystol-Myers Squibb Company |
Compounds for modulating ret protein
|
|
WO2024097989A1
(en)
|
2022-11-04 |
2024-05-10 |
Bristol-Myers Squibb Company |
Ret-ldd protein degraders
|
|
WO2024097980A1
(en)
|
2022-11-04 |
2024-05-10 |
Bristol-Myers Squibb Company |
Ret-ldd protein inhibitors
|
|
WO2024254189A1
(en)
|
2023-06-06 |
2024-12-12 |
Daré Bioscience, Inc. |
Compositions and methods for treating vulvar and vaginal atrophy (vva)
|
|
WO2025006753A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|